174 related articles for article (PubMed ID: 36146783)
1. The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
De Clercq E
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146783
[TBL] [Abstract][Full Text] [Related]
2. The Holý Trinity: the acyclic nucleoside phosphonates.
De Clercq E
Adv Pharmacol; 2013; 67():293-316. PubMed ID: 23886004
[TBL] [Abstract][Full Text] [Related]
3. Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
De Clercq E
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960679
[TBL] [Abstract][Full Text] [Related]
4. The acyclic nucleoside phosphonates (ANPs): Antonín Holý's legacy.
De Clercq E
Med Res Rev; 2013 Nov; 33(6):1278-303. PubMed ID: 23568857
[TBL] [Abstract][Full Text] [Related]
5. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
De Clercq E
Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
[TBL] [Abstract][Full Text] [Related]
7. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
De Clercq E
Biochem Pharmacol; 2011 Jul; 82(2):99-109. PubMed ID: 21501598
[TBL] [Abstract][Full Text] [Related]
8. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq E
Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
10. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
De Clercq E
Biochem Pharmacol; 2018 Jul; 153():2-11. PubMed ID: 29225131
[TBL] [Abstract][Full Text] [Related]
11. Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.
Dickson S; Gabriel N; Hernandez I
AIDS; 2022 Dec; 36(15):2225-2227. PubMed ID: 36205353
[TBL] [Abstract][Full Text] [Related]
12. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.
De Clercq E
Antiviral Res; 2007 Jul; 75(1):1-13. PubMed ID: 17116336
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Murata K; Tsukuda S; Suizu F; Kimura A; Sugiyama M; Watashi K; Noguchi M; Mizokami M
Hepatology; 2020 May; 71(5):1533-1545. PubMed ID: 31529730
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Naing C; Poovorawan Y; Tong KS
BMC Infect Dis; 2018 Nov; 18(1):564. PubMed ID: 30428847
[TBL] [Abstract][Full Text] [Related]
15. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
16. Dancing with chemical formulae of antivirals: a personal account.
De Clercq E
Biochem Pharmacol; 2013 Sep; 86(6):711-25. PubMed ID: 23876344
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
18. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
Schinazi RF; Bassit L; Clayton MM; Sun B; Kohler JJ; Obikhod A; Arzumanyan A; Feitelson MA
Antimicrob Agents Chemother; 2012 Dec; 56(12):6186-91. PubMed ID: 22985879
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
